Free Access
Issue
Med Sci (Paris)
Volume 23, Number 6-7, Juin-Juillet 2007
Page(s) 565 - 567
Section Nouvelles
DOI https://doi.org/10.1051/medsci/20072367565
Published online 15 June 2007
  1. Toledo F, Wahl GM. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6 : 909–23. [Google Scholar]
  2. Vousden KH. Outcomes of p53 activation: spoilt for choice. J Cell Sci 2006; 119 : 5015–20. [Google Scholar]
  3. Jia H. Controversial Chinese gene-therapy drug entering unfamiliar territory. Nat Rev Drug Discov 2006; 5 : 269–70. [Google Scholar]
  4. Wiman KG. Strategies for therapeutic targeting of the p53 pathway in cancer. Cell Death Differ 2006; 13 : 921–6. [Google Scholar]
  5. Vassilev LT. MDM2 inhibitors for cancer therapy. Trends Mol Med 2007; 13 : 23–31. [Google Scholar]
  6. Sherr CJ. Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 2006; 6 : 663–73. [Google Scholar]
  7. Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006; 444 : 61–6. [Google Scholar]
  8. Toledo F, Krummel KA, Lee CJ, et al. A mouse p53 mutant lacking the proline rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell 2006; 9 : 273–85. [Google Scholar]
  9. Francoz S, Froment P, Bogaerts S, et al. Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. Proc Natl Acad Sci USA 2006; 103 : 3232–7. [Google Scholar]
  10. Ronai Z. Balancing Mdm2: a Daxx-HAUSP matter. Nat Cell Biol 2006; 8 : 790–1. [Google Scholar]
  11. Brummelkamp TR, Fabius AW, Mullenders J, et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2 : 202–6. [Google Scholar]
  12. Ringshausen I, O’Shea C, Finch AJ, et al. Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell 2006; 10 : 501–14. [Google Scholar]
  13. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature 2007; 445 : 661–5. [Google Scholar]
  14. Xue W, Zender L, Miething C, et al. Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 2007; 445 : 656–60. [Google Scholar]
  15. Martins CP, Brown-Swigart L, Evan GI. Modeling the therapeutic efficacy of p53 restoration in tumors. Cell 2006; 127 : 1323–34. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.